Zobrazeno 1 - 10
of 271
pro vyhledávání: '"E, Krykowski"'
Publikováno v:
European Journal of Haematology. 58:109-113
Autoimmune haemolytic anaemia (AIHA) is one of the major complications in chronic lymphocytic leukaemia (CLL). Treatment with alkylating agents and the adenosine analogue, fludarabine, might trigger the development of AIHA in CLL patients despite the
Autor:
Wieslaw Nowak, Barbara Zdziarska, M Błasińska-Morawiec, M. Dwilewicz-Trojaczek, M. Adamczyk-Cioch, E. Krykowski, Anna Dmoszynska, Trepińska E, M. Kazimierczak, Aleksander B. Skotnicki, Andrzej Hellmann, Z. Kuratowska, Krzysztof Lewandowski, I. Urasiński, Tadeusz Robak
Publikováno v:
Scopus-Elsevier
Eosinophilia and allergic skin reactions are uncommon events after 2-chlorodoxyadenosine (2-CdA, cladribine) administration. A multicentre retrospective analysis of eosinophilia in 360 patients treated with 2-CdA for lymphoid malignancies has been ma
Autor:
R. Kordek, Krzysztof Warzocha, H. Urbańska-Ryś, Tadeusz Robak, J. Z. Boński, B. Strzelecka, J. Bartkowiak, E. Krykowski
Publikováno v:
European Journal of Haematology. 67:322-327
Patients with chronic lymphocytic leukemia (CLL) may develop a large-cell transformation known as Richter's syndrome (RS). RS usually presents as diffuse large-cell lymphoma (DLCL) or its immunoblastic variant, and it can be recognized simultaneously
Publikováno v:
Leukemia & Lymphoma. 32:359-363
The aim of our phase II study was to determine the effectiveness of combined chemotherapy consisting of 2-hour intravenous infusion of 2-CdA, mitoxantrone and dexamethasone (CMD) regimen in the treatment of heavily previously treated patients with re
Autor:
Tadeusz Robak, M Komarnicki, Trepińska E, E. Krykowski, Lech Konopka, Anna Dmoszynska, Aleksander B. Skotnicki, Jacek Roliński, M Kaźmierczuk, Wieslaw Nowak, Barbara Zdziarska, J. Hansz, I. Urasiński, Jerzy Z. Blonski, M Błasińska-Morawiec, S. Kotlarek-Haus
Publikováno v:
European Journal of Cancer. 33:2347-2351
2-Chlorodeoxyadenosine (2-CdA) is a new antimetabolite chemotherapeutic agent active in indolent lymphoid malignancies. In this retrospective study, 69 previously untreated patients with B-cell chronic lymphocytic leukaemia (B-CLL) were treated with
Publikováno v:
Leukemia & Lymphoma. 25:381-385
Three patients with B-prolymphocytic variant of HCL (HCL-V) were treated with a chlorinated purine analogue, 2-chlorodeoxyadenosine, at a daily dosage of 0.12 mg/kg in 2-hour intravenous infusion for 5 consecutive days. Partial remission was achieved
Publikováno v:
International Journal of Pharmaceutics. 135:167-176
The effects of anthracyclines on the structure of human erythrocytes were examined by flow cytometry and electron spin resonance spectroscopy. Erythrocytes were exposed to adriamycin, aclarubicin and daunorubicin at 37°C and at higher temperatures.
Autor:
M. Kazimierczak, S. Kotlarek-Haus, Tadeusz Robak, L Usnarska-Zubkiewicz, Andrzej Hellmann, Z. Kuratowska, Barbara Zdziarska, M Błasińska-Morawiec, Paweł Grieb, Jadwiga Dwilewicz-Trojaczek, Jan Maciej Zaucha, E. Krykowski, J. Hołowiecki, L Urasiński, J. Hansz, M. Krawczyk-Kulis, Stanisław Maj, M Komarnicki, Lech Konopka
Publikováno v:
Leukemia & Lymphoma. 22:107-111
Forty one patients with hairy cell leukemia (HCL) were treated with 2-chloro-deoxyadenosine (2-CdA) administered in various schedules. Complete remission (CR) was achieved in 31 (76%) patients and partial remission (PR) in 9 (22%). The mean duration
Publikováno v:
Leukemialymphoma. 46(6)
Merkel cell carcinoma (MCC) is an uncommon, neuroendocrine skin tumor with an aggressive clinical course. The etiology of the disease is unknown, although sun exposure and immunosuppression may play a role in its development. Coexistence of MCC with
Expression of the multidrug resistance-associated protein (mrp) gene in chronic lymphocytic leukemia
Autor:
Tadeusz Robak, PrzemysŁaw Juszczyński, Wojciech Niewiarowski, E. Krykowski, Krzysztof Warzocha
Publikováno v:
Leukemialymphoma. 43(1)
In order to define more accurately the role of multidrug resistance (MDR)-related protein (mrp) gene in chronic lymphocytic leukemia (CLL), we addressed the question of its expression pattern in isolated peripheral blood B lymphocytes in seven health